scholarly article | Q13442814 |
P356 | DOI | 10.1007/S40618-017-0717-8 |
P698 | PubMed publication ID | 28634704 |
P2093 | author name string | L Bartalena | |
E Piantanida | |||
P2860 | cites work | MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials | Q28077018 |
Graves' Disease. | Q30243909 | ||
Teprotumumab for Thyroid-Associated Ophthalmopathy. | Q34556184 | ||
Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. | Q35055076 | ||
Randomized controlled trial of rituximab in patients with Graves' orbitopathy | Q35055124 | ||
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy | Q36811289 | ||
Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any). | Q38869637 | ||
Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy | Q38877933 | ||
Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy? | Q38972962 | ||
Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy | Q58109526 | ||
P433 | issue | 8 | |
P304 | page(s) | 885-887 | |
P577 | publication date | 2017-06-20 | |
P1433 | published in | Journal of Endocrinological Investigation | Q15766847 |
P1476 | title | Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy? | |
P478 | volume | 40 |
Q89620715 | Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy |
Q97421343 | Teprotumumab: a disease modifying treatment for graves' orbitopathy |
Q50254727 | Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients |
Search more.